Pfizer Inc. (PFE)
Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B
Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.
Pfizer to buy Metsera in deal worth up to $10 billion
Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo's bid that it had previously called superior.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
5 Things to Know Before the Stock Market Opens
Stock futures are surging this morning after U.S. lawmakers passed a key procedural hurdle as part of an agreement that could bring an end to the shutdown that has lasted nearly six weeks; President Donald Trump has proposed issuing $2,000 “dividend” checks to Americans that would be funded by revenue from tariffs; AI data center firm CoreWeave (CRWV) is set to release its quarterly results after the closing bell today; and shares of Metsera (MTSR) are plunging after the weight-loss drug maker announced that it would be acquired by Pfizer (PFE) after a bidding war with Novo Nordisk (NVO). Here's what you need to know today.
U.S. Senate Makes Progress on Shutdown Deal, Novo Nordisk Loses Out to Pfizer
The U.S. Senate progressed a deal towards ending the longest U.S. Government shutdown in history. Eight democrats joined all but one republican in voting to move forward with a funding bill that will keep the U.S. Government liquid through January 30th, drawing rebuke from Democratic party leaders given the deal's lack of guarantees on healthcare.
Pfizer has agreed to buy weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting rival Novo Nordisk following a heated bidding war
Pfizer prevails over rival Novo Nordisk after an unusual bidding war for the weight-loss startup.
Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call
Pfizer faces a fierce bidding war with Novo Nordisk over Metsera while securing a landmark U.S. drug pricing deal.
What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?
Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment their pipeline in the booming weight-loss drug market.
Metsera weighs rival bids from Pfizer, Novo in $10 billion obesity drug battle
A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker Novo Nordisk locked in a $10 billion battle with U.S. rival Pfizer to win Metsera's obesity drug assets.
Wall Street Breakfast Podcast: Government Shutdown Hits New Altitude
FAA will reduce air traffic by 10% across 40 major markets due to staffing shortages from the government shutdown, impacting 3,500-4,000 flights daily. Pfizer (PFE) has matched Novo Nordisk's bid for obesity biotech Metsera (MTSR), valuing it at $10 billion, intensifying the takeover battle.
Pfizer: Market Still Pricing It At Crisis Valuations
Pfizer Inc. remains materially undervalued despite recent volatility, with its recovery momentum challenged by the ongoing Metsera bidding war. PFE's more stable guidance and robust pipeline offer multiple growth pathways, even if the Metsera acquisition turns out to be unsuccessful. The GLP-1 market's increasing competition and pricing pressures may weigh on PFE sentiment, but strong free cash flows and appealing dividend yield support a bullish view.
Healthy Returns: What to know about Pfizer and Novo Nordisk's bidding war over obesity biotech Metsera
Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to extending tax credits.
